SCHEMBL4830285

SCHEMBL4830285

Fc1ccc(-c2nc(Br)c(Br)n2Cc2ccccc2)c(F)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.41
HK1 P19367 1/20 0.41
HTT P42858 1/20 0.41
HKDC1 Q2TB90 1/20 0.41
POLB P06746 1/20 0.40
CYP11B2 P19099 1/20 0.40
GRM2 Q14416 1/20 0.39
KDM4E B2RXH2 2/20 0.39
ALDH1A1 P00352 2/20 0.39
GAA P10253 2/20 0.39
LMNA P02545 1/20 0.39
CD74 P04233 1/20 0.39
MIF P14174 1/20 0.39
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
BRD4 O60885 1/20 0.37
MAPK14 Q16539 3/20 0.37
BCHE P06276 1/20 0.37
ACHE P22303 1/20 0.37
BACE1 P56817 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6209619 0.84 ALDH1A1 (0.42) MAPTHK1HTTHKDC1POLB
SCHEMBL4833510 0.84 ALDH1A1 (0.43) MAPTHK1HTTHKDC1POLB
SCHEMBL6209919 0.80 MAPT (0.47) MAPTHK1HTTHKDC1CYP11B2
SCHEMBL989287 0.80 TNF (0.45) MAPTHK1HTTHKDC1CYP11B2
SCHEMBL4533975 0.73 ALDH1A1 (0.39) MAPTHK1HTTHKDC1CYP11B2
SCHEMBL27007784 0.72 KMT2A (0.44) MAPTPOLBKDM4EALDH1A1GAA
SCHEMBL990110 0.71 CYP2C19 (0.42) MAPTHK1HTTHKDC1POLB
SCHEMBL4836206 0.70 MAPT (0.61) MAPTHTTHKDC1POLBKDM4E
SCHEMBL4838632 0.70 ADORA2A (0.49) MAPTKDM4EALDH1A1GAALMNA
SCHEMBL5582032 0.68 TP53 (0.56) MAPTHTTGRM2KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7320995-B2 Benzimidazoles and benzothiazoles as inhibitors of map kinase ELI LILLY AND COMPANY (US) 2008-01-22 US disclosed
EP-1554272-B1 BENZIMIDAZOLES AND BENZOTHIAZOLES AS INHIBITORS OF MAP KINASE LILLY CO ELI (US) 2006-10-25 EP disclosed
US-20050272791-A1 Benzimidazoles and benzothiazoles as inhibitors of map kinase EIL LILLY AND COMPANY (US) 2005-12-08 US disclosed
EP-1554272-A1 BENZIMIDAZOLES AND BENZOTHIAZOLES AS INHIBITORS OF MAP KINASE ELI LILLY AND COMPANY (US) 2005-07-20 EP disclosed
WO-2004014900-A1 BENZIMIDAZOLES AND BENZOTHIAZOLES AS INHIBITORS OF MAP KINASE ELI LILLY AND COMPANY (US) 2004-02-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050272791-A1 Benzimidazoles and benzothiazoles as inhibitors of map kinase MAP3K8, MAPK8, MAPK1 MAPT 1235/4885HK1 1941/4885HTT 4541/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.